Similar articles

• The suppression of primary palmar-plantar hyperhidrosis by topiramate.

  Owen DB, Meffert JJ. Owen DB, et al. Br J Dermatol. 2003 Apr;148(4):826-7. doi: 10.1046/j.1365-2133.2003.05237.x. Br J Dermatol. 2003. PMID: 12752152 No abstract available.
• Reversible nonfluent aphasia and left frontal hypoperfusion during topiramate treatment.

  Cappa SF, Ortelli P, Garibotto V, Zamboni M. Cappa SF, et al. Epilepsy Behav. 2007 Feb;10(1):192-4. doi: 10.1016/j.yebeh.2006.11.001. Epub 2006 Dec 12. Epilepsy Behav. 2007. PMID: 17166774
• Cognitive effects of topiramate in migraine patients aged 12-17 years.

  Jokeit H, Reed V. Jokeit H, et al. Pediatr Neurol. 2011 May;44(5):396; author reply 396-7. doi: 10.1016/j.pediatrneurol.2011.01.015. Pediatr Neurol. 2011. PMID: 21481754 Clinical Trial. No abstract available.
• Question 3. Topiramate for chronic migraine in children.

  Jayapal S, Maheshwari N. Jayapal S, et al. Arch Dis Child. 2011 Mar;96(3):318-21. doi: 10.1136/adc.2011.211151. Arch Dis Child. 2011. PMID: 21317129 Review. No abstract available.
• Focus on topiramate in neuropathic pain.

  Dib JG. Dib JG. Curr Med Res Opin. 2004 Dec;20(12):1857-61. doi: 10.1185/030079904X11358. Curr Med Res Opin. 2004. PMID: 15701203 Review.